Skip to main content
padlock icon - secure page this page is secure

Treatment of Guillain‐Barré syndrome and CIDP

Buy Article:

$52.00 + tax (Refund Policy)

Abstract 

Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating poly‐(radiculo)neuropathy (CIDP) are immune-mediated disorders with a variable duration of progression and a range in severity of weakness. Infections can trigger GBS and exacerbate CIDP. Anti-ganglioside antibodies are important, but there is debate on the role of genetic factors in the pathogenesis of these disorders. Randomized controlled trials (RCT) have shown that intravenous immunoglobulin (IVIg) and plasma exchange (PE) are effective in both GBS and CIDP. Most CIDP patients also improve after steroid therapy. Despite current treatment options, many patients have residual deficits or need to be treated for a long period of time. Therefore, new treatment trials are highly indicated. This review focuses on the current and possible new treatment options that could be guided by recent results from laboratory experiments.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CIDP; GBS; Guillain‐Barré syndrome; Miller–Fisher syndrome; chronic inflammatory demyelinating poly(radiculo)neuropathy; intravenous immunoglobulin; methylprednisolon; plasma exchange; steroids

Document Type: Research Article

Affiliations: Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands

Publication date: June 1, 2005

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more